• Inicio
  • Resultados de la búsqueda
  • Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study.

Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study.

BJOG : an international journal of obstetrics and gynaecology (2013-03-16)
K Nezvalová-Henriksen, O Spigset, H Nordeng
RESUMEN

To investigate the individual effects of ibuprofen, diclofenac, naproxen, and piroxicam on pregnancy outcome. Cohort study. Norwegian population. A total of 90 417 women and singleton child pairs. The Norwegian Mother and Child Cohort Study and Medical Birth Registry of Norway data sets were used. Infant survival, congenital malformations, structural heart defects, neonatal complications, haemorrhage during pregnancy and postpartum, asthma at age of 18 months. One or more of the four nonsteroidal anti-inflammatory drugs (NSAIDs) were used by 6511 pregnant women (7.2%). No effect on rates of infant survival, congenital malformation, or structural heart defects was found. The use of ibuprofen in the second trimester was significantly associated with low birthweight (adjusted OR 1.7, 95% CI 1.3-2.3), and ibuprofen use in the second and third trimesters was significantly associated with asthma in 18-month-old children (adjusted OR 1.5, 95% CI 1.2-1.9; adjusted OR 1.5, 95% CI 1.1-2.1). The use of diclofenac in the second trimester was significantly associated with low birthweight (adjusted OR 3.1, 95% CI 1.1-9.0), whereas diclofenac use in the third trimester was significantly associated with maternal vaginal bleeding (adjusted OR 1.8, 95% CI 1.1-3.0). No associations with other neonatal complications were found. The lack of associations with congenital malformations is reassuring. The significant association between diclofenac and ibuprofen use late in pregnancy, and maternal bleeding and asthma in the child, respectively, is consistent with their pharmacological effects. The increased risk of low birthweight may partly have been caused by underlying inflammatory conditions, and was reassuringly similar to the expected baseline risk of low birthweight.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ibuprofen, ≥98% (GC)
Supelco
Ibuprofen, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Diclofenac sodium salt
Supelco
Diclofenac sodium salt, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(S)-(+)-Ibuprofen, ReagentPlus®, 99%
Supelco
Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Naproxen, meets USP testing specifications
Supelco
Ibuprofen sodium salt, analytical standard, ≥98% (GC)
Ibuprofen for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Ibuprofen
Ibuprofen, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Piroxicam, ≥98% (TLC)
Sigma-Aldrich
Ibuprofen, meets USP testing specifications
Sigma-Aldrich
(S)-(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, 98%
Diclofenac sodium, European Pharmacopoeia (EP) Reference Standard
Piroxicam for system suitability
Supelco
Naproxen, VETRANAL®, analytical standard
Naproxen, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Piroxicam, meets USP testing specifications
Piroxicam, European Pharmacopoeia (EP) Reference Standard
Diclofenac potassium, European Pharmacopoeia (EP) Reference Standard

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.